Clinical Trials

65 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

362 enrolled

HER2-positive Metastatic Breast Cancer

NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

78 enrolled

HER2 Positive Metastatic Breast Cancer

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

120 enrolled

Breast Neoplasms

NCT05823623 2023-09-14

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Breast Neoplasms

NCT05880927 2023-05-30

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

150 enrolled

Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

41 enrolled

Breast Neoplasms

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Neoplasms

NCT05621434 2022-11-18

A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

63 enrolled

Breast Neoplasms

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

126 enrolled

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05429294 2022-06-23

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

209 enrolled

HER2-positive Breast Cancer

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

34 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT05318339 2022-04-08

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Genitourinary

Carcinoma, Transitional Cell

NCT05255523 2022-02-24

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Advanced Breast Cancer

NCT05111444 2021-11-08

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

65 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05076695 2021-10-13

NeoTPPF

37 enrolled

Estrogen Receptor-positive Breast Cancer

NCT05020964 2021-08-25

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

68 enrolled

Advanced Breast Cancer

NCT04380012 2021-07-15

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

100 enrolled

Breast Neoplasms

NCT04960943 2021-07-14

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Gastrointestinal

Digestive System Neoplasms

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Breast Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

120 enrolled

CNS

Brain Neoplasms

NCT04900311 2021-05-25

Pyramid

490 enrolled

HER2+ Early or Locally Advanced Breast Cancer

NCT04858516 2021-04-26

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

57 enrolled

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04659499 2020-12-09

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

261 enrolled

Breast Neoplasms

NCT04639271 2020-11-20

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

100 enrolled

Breast Neoplasms

NCT04255056 2020-02-07

PRETTY

27 enrolled

Breast Neoplasms

NCT04246502 2020-02-05

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

200 enrolled

Breast Neoplasms

NCT04236310 2020-01-22

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

37 enrolled

Breast Neoplasms

NCT04179656 2019-11-27

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

100 enrolled

Other solid neoplasm

Solid Tumor

NCT04095390 2019-09-19

INPHASE

Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

77 enrolled

Breast Diseases, Breast Neoplasms

NCT04063462 2019-08-21

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04033172 2019-07-25

Pyrotinib

40 enrolled

Breast Neoplasms

NCT03997539 2019-06-25

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

256 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

35 enrolled

Breast Neoplasms

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

32 enrolled

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

250 enrolled

Breast Diseases, Breast Neoplasms

NCT03412383 2018-01-30

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

14 enrolled

Breast Neoplasms

NCT02535507 2015-08-28

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer